Hospital Cuf Tejo S.A. — Clinical Trial Site

29 Registered trials

18 Currently recruiting

Organisation

Hospital Cuf Tejo S.A.

Location

Lisbon, Portugal

Identifier

ORG-100043243

Address

Avenida 24 De Julho 171a, 1350-345, Portugal

Departments

5802:Oncologia
Cardiologia
Cardiology
Departamento de Medicina Interna
Departamento de oncología
Immunoallergology
Medical Oncology
Medical Oncology and Hematology
Oncologia
Oncologia Médica
Oncology
Pneumologia
Psychiatry
Serviço de Medicina Interna
Serviço de Oncologia
urology
Urology Department

Clinical trials at this site (29)

Search interface

Grass/Olive Immunotherapy for Rhinitis and Asthma (GOES) Recruiting

2025-521709-42-00 Allergic rhinoconjunctivitis with or without asthma due 5 2026-06-23
Grass Immunotherapy for Rhinitis and Asthma (GIRA) Recruiting

2025-521736-10-00 Allergic rhinoconjunctivitis with or without controlled 5 2026-06-23
A Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants with Progressive Pulmonary Fibrosis Recruiting

2023-503699-25-00 Progressive Pulmonary Fibrosis 5 2024-07-15
A Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants with Idiopathic Pulmonary Fibrosis Recruiting

2023-503697-21-01 Idiopathic pulmonary fibrosis 5 2024-06-24
BEAMION Lung-2: A study to test whether zongertinib (BI 1810631) helps people with advanced non-small cell lung cancer with HER2 mutations c… Recruiting

2023-504308-27-00 non-squamous non-small cell lung cancer 5 2024-06-06
A study to test whether different doses of BI 764532 help people with small cell lung cancer or other neuroendocrine cancers Recruiting

2023-504247-13-00 Small Cell Lung Cancer 4 2023-10-17
Phase 2 Study of Adagrasib Monotherapy and in Combination With Pembrolizumab and Phase 3 Study of Adagrasib in Combination with Pembrolizuma… Recruiting

2023-508922-83-00 Advanced Non-Small Cell Lung Cancer 10 2021-03-17
A clinical study of opevesostat and standard hormone therapy in people with prostate cancer (MK-5684-004) Recruiting

2023-504957-11-00 Metastatic castration resistant prostate cancer 5 2026-03-24
Beamion LUNG-3: A study to test whether zongertinib helps people with surgically removed, non-small cell lung cancer with HER2 mutations com… Recruiting

2025-521284-12-00 Non-small cell lung cancer 5 2026-03-05
ZENITH: Zilebesiran in Patients with Hypertension Not Adequately Controlled and With Either Established Cardiovascular Disease or High Risk … Recruiting

2025-522960-34-00 Established cardiovascular disease 5 2026-02-09
A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous… Recruiting

2025-520730-28-00 Common EGFR-Mutated Locally Advanced or Metastatic Non- 4 2025-12-08
A phase III, randomized, open-label, blinded endpoint, comparative trial of ferric derisomaltose versus no intravenous iron in iron-deficien… Recruiting

2024-519059-28-00 Chronic Heart Failure 5 2025-07-17
A Randomized, Double-blinded, Multicenter, Phase Ⅲ Clinical Study of HLX22 (Recombinant Humanized Anti-HER2 Monoclonal Antibody Injection) i… Recruiting

2024-516633-12-00 Locally advanced/ metastatic gastroesophageal junction 5 2025-06-30
A study to understand if sotagliflozin improves symptoms and is safe in people with hypertrophic cardiomyopathy Recruiting

2024-513869-39-00 Obstructive Cardiomyopathy, Hypertrophic 5 2025-06-27
Sotorasib, Panitumumab and FOLFIRI Versus FOLFIRI With or Without Bevacizumab-awwb in Treatment-naïve Subjects With Metastatic Colorectal Ca… Recruiting

2022-502352-31-00 Colorectal Cancer (CRC) 5 2025-02-10
A clinical study to compare MK-2870 with pembrolizumab to pembrolizumab alone in people with lung cancer (MK-2870-007) Recruiting

2023-503376-24-00 Metastatic non-small cell lung cancer (NSCLC) 5 2024-03-20
An international, multicenter, randomised, superiority phase III, open label, 2-arm study to investigate distant metastasis free survival wi… Recruiting

2022-501453-36-00 Breast cancer 5 2024-02-23
A Study of Olezarsen (ISIS 678354) Administered Subcutaneously to Participants with Severe Hypertriglyceridemia (SHTG) Recruiting

2022-501999-26-00 Severe Hypertriglyceridemia (SHTG) 5 2023-07-12
Study Comparing Tarlatamab, Durvalumab, Carboplatin, and Etoposide versus Durvalumab, Carboplatin, and Etoposide in First-Line ES-SCLC (DeLL… Ended

2024-520050-38-00 Extensive stage small cell lung cancer (ES-SCLC). 5 2025-09-18
A multicentre, Phase II, single-arm, interventional study of neoadjuvant durvalumab and platinum-based chemotherapy (CT), followed by either… Ended

2023-503357-35-00 Non-small Cell Lung Cancer (NSCLC) 4 2024-03-20
A Phase 3 Study of Front‑line Platinum Doublet Therapy With Sotorasib Versus Pembrolizumab in PD-L1 Negative KRAS p.G12C Positive Advanced/M… Ended

2022-501863-41-00 Subjects With Stage IV or Advanced Stage IIIB/C Nonsqua 5 2023-11-13
A study to compare the study treatment darolutamide in combination with androgen deprivation therapy (ADT) to placebo in combination with AD… Ended

2022-501343-33-00 Biochemically recurrent prostate cancer 5 2023-10-18
Treatment combination of Durvalumab, Tremelimumab, Enfortumab Vedotin in patients with muscle invasive bladder cancer ineligible to cisplati… Ended

2023-507342-84-00 Bladder Cancer 5 2021-10-26
A Study Evaluating the Efficacy and Safety of Adjuvant Atezolizumab or Placebo and Trastuzumab Emtansine for Participants With HER2-Positive… Ended

2023-503568-18-00 Early human epidermal growth factor receptor 2 (HER2) p 5 2021-04-13